- Home
- BBBY vs TYRA Comparison
BBBY vs TYRA Comparison
Compare BBBY & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBBY
- TYRA
- Stock Information
- Founded
- BBBY 1971
- TYRA 2018
- Country
- BBBY United States
- TYRA United States
- Employees
- BBBY N/A
- TYRA N/A
- Industry
- BBBY
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- BBBY
- TYRA Health Care
- Exchange
- BBBY Nasdaq
- TYRA Nasdaq
- Market Cap
- BBBY 573.5M
- TYRA 681.7M
- IPO Year
- BBBY N/A
- TYRA 2021
- Fundamental
- Price
- BBBY $10.96
- TYRA $13.37
- Analyst Decision
- BBBY
- TYRA Strong Buy
- Analyst Count
- BBBY 0
- TYRA 7
- Target Price
- BBBY N/A
- TYRA $30.71
- AVG Volume (30 Days)
- BBBY 2.6M
- TYRA 186.4K
- Earning Date
- BBBY 10-23-2025
- TYRA 11-06-2025
- Dividend Yield
- BBBY N/A
- TYRA N/A
- EPS Growth
- BBBY N/A
- TYRA N/A
- EPS
- BBBY N/A
- TYRA N/A
- Revenue
- BBBY $1,128,578,000.00
- TYRA N/A
- Revenue This Year
- BBBY N/A
- TYRA N/A
- Revenue Next Year
- BBBY $11.57
- TYRA N/A
- P/E Ratio
- BBBY N/A
- TYRA N/A
- Revenue Growth
- BBBY N/A
- TYRA N/A
- 52 Week Low
- BBBY $3.54
- TYRA $6.42
- 52 Week High
- BBBY $12.65
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- BBBY 62.83
- TYRA 59.29
- Support Level
- BBBY $9.05
- TYRA $12.98
- Resistance Level
- BBBY $12.65
- TYRA $13.92
- Average True Range (ATR)
- BBBY 0.83
- TYRA 0.62
- MACD
- BBBY 0.19
- TYRA 0.00
- Stochastic Oscillator
- BBBY 55.33
- TYRA 54.70
About BBBY Bed Bath & Beyond Inc.
Bed Bath & Beyond Inc is an ecommerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands, offering a comprehensive array of products and services that enable its customers to enhance everyday life through quality, style, and value. The Company currently owns Bed Bath & Beyond, Overstock, buybuy BABY, and other related brands and websites as well as a blockchain asset portfolio.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.